Oruka Therapeutics (ORKA) Other Non-Current Assets (2010 - 2026)
Oruka Therapeutics' quarterly Other Non-Current Assets came in at $103000.0 in Q1 2026, little changed year-on-year from $103000.0 in Q1 2025, and little changed quarter-over-quarter from $103000.0 in Q4 2025.
Oruka Therapeutics has reported Other Non-Current Assets for 17 years, with the latest figure at $103000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $103000.0; the trailing twelve-month figure through Mar 2026 stood at $103000.0 (changed 0.0% YoY), and the FY2025 full-year result was $103000.0, up 139.53% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $103000.0, roughly flat from $103000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $103000.0 in Q1 2025, with the low at $12000.0 in Q3 2023.
- Average Other Non-Current Assets over 5 years is $44529.4, with a median of $18000.0 recorded in 2022.
- Year-over-year, Other Non-Current Assets sank 33.33% in 2023 and soared 758.33% in 2025.
- Tracing ORKA's Other Non-Current Assets over 5 years: stood at $18000.0 in 2022, then plunged by 33.33% to $12000.0 in 2023, then soared by 258.33% to $43000.0 in 2024, then jumped by 139.53% to $103000.0 in 2025, then changed by 0.0% to $103000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $103000.0 (Q1 2026), $103000.0 (Q4 2025), and $103000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | 103,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Sep 30, 2025 | 103,000.00 |
| Jun 30, 2025 | 103,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Dec 31, 2024 | 43,000.00 |
| Sep 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 18,000.00 |
| Mar 31, 2023 | 18,000.00 |
| Dec 31, 2022 | 18,000.00 |
| Sep 30, 2022 | 18,000.00 |
| Jun 30, 2022 | 18,000.00 |
| Mar 31, 2022 | 18,000.00 |
| Dec 31, 2021 | 18,000.00 |
| Sep 30, 2021 | 18,000.00 |
| Jun 30, 2021 | 18,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | 12,000.00 |
| Sep 30, 2020 | 36,000.00 |
| Jun 30, 2020 | 24,000.00 |
| Mar 31, 2020 | 24,000.00 |
| Dec 31, 2019 | 24,000.00 |
| Sep 30, 2019 | 24,000.00 |
| Jun 30, 2019 | 24,000.00 |
| Mar 31, 2019 | 24,000.00 |
| Dec 31, 2018 | 24,000.00 |
| Sep 30, 2018 | 24,000.00 |
| Jun 30, 2018 | 24,000.00 |
| Mar 31, 2018 | 24,000.00 |
| Dec 31, 2017 | 24,000.00 |
| Sep 30, 2017 | 497,000.00 |
| Jun 30, 2017 | 587,000.00 |
| Mar 31, 2017 | 676,000.00 |
| Dec 31, 2016 | 766,000.00 |
| Sep 30, 2016 | 855,000.00 |
| Jun 30, 2016 | 816,000.00 |
| Mar 31, 2016 | 580,000.00 |
| Dec 31, 2015 | 630,000.00 |
| Sep 30, 2015 | 679,000.00 |
| Jun 30, 2015 | 754,000.00 |
| Mar 31, 2015 | 553,000.00 |
| Dec 31, 2014 | 608,000.00 |
| Sep 30, 2014 | 548,000.00 |
| Jun 30, 2014 | 831,000.00 |
| Mar 31, 2014 | 828,000.00 |
| Dec 31, 2013 | 130,000.00 |
| Sep 30, 2013 | 100,000.00 |
| Jun 30, 2013 | 104,000.00 |
| Mar 31, 2013 | 124,000.00 |
| Dec 31, 2012 | 144,000.00 |
| Sep 30, 2012 | 164,000.00 |
| Jun 30, 2012 | 183,000.00 |
| Mar 31, 2012 | 204,000.00 |
| Dec 31, 2011 | 224,000.00 |
| Sep 30, 2011 | 244,000.00 |
| Jun 30, 2011 | 264,000.00 |
| Dec 31, 2010 | 304,000.00 |